Overview
Prilenia is a biopharmaceutical company focused on developing neuroprotective therapies targeting the sigma-1 receptor for neurodegenerative and neuropsychiatric diseases. The company combines drug development expertise with global operations to advance disease-modifying treatments and ensure patient access to innovative neurological therapies.
More in Neurotechnology
Latest industry news
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
A New Neurotech Startup Launches to Challenge Sam Altman's Merge Labs in the BCI Race
2026-10-10 · Industry
Butterfly Network Teams Up With Bridge Neurotech to Chase Ultrasound-Based Brain-Computer Interfaces
2026-10-09 · Industry
Paradromics Hits Four-Year Mark for Stable Neural Recording in Landmark BCI Durability Milestone
2026-10-08 · Research
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →